Back to Bella
Nu.Q Nucleosome
Emerging1 reading · tracked as a trend, not scored against a reference range
Latest
21ng/mL
Trend
Baseline established — a second reading sets the direction.
What this is
A circulating-nucleosome cancer screen (Volition Nu.Q, distributed via IDEXX/Antech); flags systemic cancers such as lymphoma and haemangiosarcoma.
Why it’s experimental
A screening aid, not a diagnosis: a raised result must be confirmed with imaging/biopsy, and inflammation can raise nucleosomes.
Frontier markers are tracked for their direction of travel. They do not count toward the Healthspan Score, carry no optimal range, and are not diagnostic — discuss any result with your veterinary surgeon.
Source & evidence →